📢It's #ESMO election time!

I am delighted to be nominated for ESMO Director of Education 😊

ALL the nominees are fantastic representing the global @myesmo.bsky.social community 🌍

🙏for all the good wishes

Rules this year for social media so that's it from me!

Now please vote 🗳️!

2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change Written by Elizabeth Smyth MD Written by Somnath Mukherjee MD, MRCP, FRCR, FRCP

We've spent 2024 discussing RT trial results in gastroesophageal cancer.

My radiation oncology mate Som helps me make sense of it all below...

2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change

prac.co/l/22cfph7u

Your Western blot module is surrounded by talismans for good fortune. Baby Yoda x 3, a troll and a slightly lost sheep. Surely, it cannot fail you now!

When the Western really has to work (via DPhil student text)
Good to see the old methods live on

Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3!

www.esmoopen.com/article/S205...

Twitter, as we knew it, is gone, stained by new horrific algorithms that promote misinformation.

🦋 is a much better place for those interested in science. And it’s growing fast.

Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.

Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in <50% of patients. Patients in the UK with o…

Good to see our protocol paper for DECIPHER in press at ESMO GO!

ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring

🧬➕ receive TDxD instead of usual post-op chemo

Hope to #cure some micrometastatic cancers 🙏

www.sciencedirect.com/science/arti...

Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!

www.nature.com/articles/s41...

Now the picture!

#OncSky has truly arrived...

@drchoueiri.bsky.social has found us at last 👏👏

Well I do hope it's Tony but there's no picture 😉

Please come back!

But even if you don't you know we will always be research buddies 🤗

OS results of KN-522 out in @NEJM. Terrific news: adding pembro to neoadjuvant chemo for TNBC saves lives (5% 5-year Δ). Bad news: we’re stuck with giving 5 drugs to all patients with stage II-III TNBC, with permanent toxicity for many. Biomarkers, please! t.co/8S9YWOP1lr

PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials Perioperative chemoimmunotherapy [i.e. chemotherapy plus immune checkpoint inhibitor (ICI) (ChT–ICI)] is an investigational treatment for operable gastroesophageal adenocarcinoma (GEA) with unclear ou...

Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏

Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:

✅Strong link between PD-L1 and pathological response.

✖️ Less so OS ..

www.esmogastro.org/article/S294...

Looking forward to MATTERHORN next year!

Next-generation combination approaches for immune checkpoint therapy - Nature Immunology In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.

www.nature.com/articles/s41...

Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang

Regular abstracts from #SABCS24 are out!

3407 pages of new breast cancer discoveries.

Find them here: sabcs.org/Portals/0/Do...

The main trial report will be in another journal (same one as TOPGEAR I imagine...)

ESOPEC too if you cover TOPGEAR. I imagine it's near publication....

ASCO annual meeting 2025 abstract submitter open - closes Jan 28th.

To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)!

Apply for a waiver when you submit an abstract

conferences.asco.org/am/abstract-...

Best case series ever 🤣..

Looking forward to seeing the other institutions & societies join too...

I've been lobbying mine 🙂

Great to see you Dr Greef 😍

EGFR-directed antibodies promote HER2 ADC internalization and efficacy Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...

NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)

Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models

#DrugDevelopment #OncoSky

www.cell.com/cell-reports...

@valdesan.bsky.social to the rescue! Oncology Vol 1 and 2 starter packs (links included in the packs)

go.bsky.app/UP8aWPd

#medsky #oncsky #oncosky #oncology

Good new for BTC patients!

Reclaiming our joy #MedSky #OncSky

valdesan@bsky.social is curating

go.bsky.app/GKXp9Fy

Happy Friday! Sharing oncology starter pack #2👇

Long-term survivorship concerns of patients with esophageal and gastric cancer - VJOncology Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the long-term survivorship concerns of patients with esophageal...

November is gastric cancer awareness month and we are sharing updates in the field ⭐

At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.

👉See the video below! 👈

https://buff.ly/48WQh5R

#stcsm #gism

Better late than never 😊👍!

Right on time for #NANETS2024: the North American Neuroendocrine Tumor Society is on @bsky.app ! Lots of posts to come from the NET community over the next three days during the Annual Symposium taking place in #Chicago. @oncothor.bsky.social @cancertrials.bsky.social @halletjulie.bsky.social

🚨The exodus of #MedTwitter #OncSky to #BlueSky @bsky.app is fascinating. All the #Twitter birds are now flying freely in the Bluesky. 🐦💙 Will #Bluesky succeed where #Threads and #Mastodon struggled?#MedTwitterMigration #BlueSkySocial @oncoalert.bsky.social @tmprowell.bsky.social